Bruker Launches D8 ADVANCE HE and D8 DISCOVER HE High-Energy XRD Systems for Batteries, Amorphous Materials, and Catalysts

Applications include structure research and operando studies of new materials for manganese-rich, sodium-ion, and all-solid-state batteries.

CRANS-MONTANA, Switzerland – Bruker today at the EPDIC 2026 announced the launch of the D8 ADVANCE HE and D8 DISCOVER HE, new X-ray diffraction systems specifically optimized for High-Energy X-Ray Diffraction (HE-XRD), expanding the ability of researchers to capture higher real-space resolution, extended total scattering range, and bulk structural information with laboratory-scale HE-XRD.

A key innovation is the new LYNXEYE HE detector based on Bruker’s proprietary CdTe-based detector technology (patent pending), featuring >99% efficiency across Cu, Mo, and Ag energies and requiring no external cooling media or infrastructure. The resulting high detection efficiency improves the performance of high-energy crystallography and Pair Distribution Function (PDF) analysis for crystalline, nanostructured, and amorphous materials.

High-energy X-rays facilitate non-destructive diffraction of bulk samples and operando investigations of electrochemical cells, reactors, and other intact devices. Dedicated solutions, such as the
TC POUCH temperature chamber, enable controlled electrochemical cycling of battery pouch cells at elevated temperatures, helping researchers directly to correlate structural changes with performance in battery materials during real-time operation.

To translate this rich scattering data into meaningful structural insight, the systems leverage Bruker’s DIFFRAC.SUITE software. The integrated software supports experiment planning, measurement execution, large dataset handling, and advanced evaluation workflows, enabling efficient analysis of complex data and high-throughput automation across large data volumes.

The D8 ADVANCE HE and D8 DISCOVER HE build on the established D8 platform and maintain full compatibility with Bruker’s extensive portfolio of X-ray optics, sample environments, and automation solutions, providing a scalable and future-proof platform for applications ranging from routine analysis to advanced research.

The D8 ADVANCE HE and the D8 DISCOVER HE enable efficient operando investigations of batteries, catalysts, and other functional materials, helping accelerate the path from materials research to final products,” said Michael Evans, XRD Product Manager, Bruker AXS. “For complex materials under real operating conditions, our customers can now see more, do more, and ultimately understand more.

D8 ADVANCE HE and D8 DISCOVER HE – HE-XRD systems for high-energy crystallography, PDF analysis, and operando investigations of intact devices, reactors, and electrochemical cells.

D8 ADVANCE HE and D8 DISCOVER HE – HE-XRD systems for high-energy crystallography, PDF analysis, and operando investigations of intact devices, reactors, and electrochemical cells.

About Bruker Corporation – Leader of the Post-Genomic Era

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with customers, Bruker is enabling innovation and customer success in post-genomic life science molecular and cell biology, in disease biology and translational research, in specialty diagnostics, in applied and biopharma applications, as well as in industrial and cleantech research and QC, and in next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology, molecular diagnostics and therapeutic drug monitoring. For more information, please visit www.bruker.com.

< | >